DDW’s Megan Thomas went to Cambridge, UK, to learn more about what’s happening in this life science epicentre. She spoke with a number of local companies and attended events, the first of which she writes about here: A conversation with Nicola Thompson, CEO of TRIMTECH Therapeutics.

E3 ligases to expand protein degradation potential

Thompson has spent years in the targeted protein degradation (TPD) space, which has long been focused on oncology, with some progress in inflammation. She says: “It’s very difficult for the field to move out into other areas. While some of that’s strategic choice or chemistry, some of it is mechanism and whether you can address targets outside of established disease areas. The excitement for TRIMTECH is that the E3 ligase mechanism we use to degrade protein aggregates is highly selective for aggregates vs functional monomeric proteins, which is very difficult for other E3 ligases to tackle. Its natural role is to remove big complexes in the cell.”

TRIMTECH’s approach opens the door to therapies for neurodegeneration, an area previously challenging for TPD. Thompson says: “I think we are lucky, because our founding scientists identified this novel E3 ligase, known as TRIM21, 20 years ago. They were very much focused on virology – and it’s a viral defence mechanism in nature. So, up to now, it has kind of bypassed the field somewhat!”

The novelty of TRIM21 brings two major advantages: a wider target space and the potential for novel chemistry. Thompson says: “Accessing the central nervous system (CNS) is also a medicinal chemistry challenge for small molecules generally and for most molecules, in fact. For CNS-based degrader molecules, we’re now starting to see that groups in certain cases can get these molecules into the brain. I think the field is feeling a little bit more bullish about getting to the CNS, even with these complex molecules which are quite difficult to modify. What we’ve developed at TRIMTECH  are starting points that have already shown good CNS penetrance.”

Thompson believes TRIMTECH’s route to the right targets is more tractable than ever. The company is unlocking targets thought to be causal in major neurodegenerative diseases. She says: “This means, for the first time, that removal of these pathological protein targets is becoming tractable to small molecules. If you think about some of these diseases, like Alzheimer’s or Parkinson’s disease, these really need small molecules to get to big populations, rather than for example, a gene therapy approach, which is ideally suited to a rare disease. So, opening up this set of targets to small molecules is exciting.”

Gene therapy, Thompson confirms, remains an option; TRIMTECH has got expression vector approaches where it can utilise its mechanism. TRIMTECH could take that approach, but she has felt for a long time that if you can apply small molecules to these big diseases, and if you can do that through targeted protein degradation, it actually removes the toxic aggregated form of tau and alpha-synuclein that drive Alzheimers’s and Parkinson’s diseases. She says: “If you can remove them from the cell with a small molecule, you really have a chance to reach so many more patients.”

Finance

TRIMTECH’s momentum is reflected in its investor support. Earlier in 2025, the company completed a $31 million (£25 million) seed funding round led by Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), joined by M Ventures, Pfizer Ventures, Eli Lilly, MP Healthcare Venture Management, Cambridge Enterprise Ventures, and Start Codon.

Thompson says: “From our investor base, we were lucky in the beginning to have CIC and DDF. They’re really cornerstones for us.” She thinks that the involvement of major pharma companies shows belief in TRIMTECH’s differentiated science. She adds: “I think it really speaks to people that understand where the gaps are, those people see how  this really could be a way to leverage a technology for the first time to tackle it. You can  see that reflected in our investor base”.

In terms of what’s planned for the money of this seed round, Thompson says it enables the company to advance its chemistry platform and drug discovery pipeline. She says: “We’re coming from the best possible foundation from a chemistry platform perspective”.

Neurodegeneration targets and beyond 

TRIMTECH’s novel mechanism allows it to pursue targets in a unique way. With an oversubscribed seed round, the company can broaden its portfolio. Thompson says: “The objective here is to take targets forward. We are starting with four targets, predominantly in neurodegeneration, but we’re not limited to neurodegenerative diseases – anywhere where we can target a protein that is causal in disease or is linked to disease – but is either in an aggregated or oligomeric complex, or a molecular machine, for example. If we can the target it multiple times, we can degrade it.”

One of the four targets is in the neuroinflammatory/inflammatory space, showing potential beyond CNS. She says: “Although we’re very focused on neurodegeneration, we are also able to move out into these other areas. So, inflammation is one that we think could be really exciting. We’ll take two programmes forward from the seed raise, and we will take them to in vivo proof-of-concept pre-clinically. Also, tolerability data: we’ll get some major derisking, essentially showing that in vivo, we can do what we’ve shown we can do with other modalities through the TRIM21 mechanism with a small molecule. That is really valuable.”

Thompson says the next raise for TRIMTECH will hopefully be larger. She explains that the purpose of this round is to set themselves up so that the next round can get them into a clinical readout. This was one of the reasons they were keen to raise a significant amount – so that they could really get some of those proof of principles, derisk the approach and also, of course, support the next round. She says: “As we know, the market is challenging at the moment, so it’s really important to be able to set yourself up so that for the next raise, investors have sight of the clinic. That helps everyone because that’s major derisking point.”

Investment ‘recipe for success’

When asked about what draws in investors, Thompson answered that she thinks there are some key ‘ingredients’ that investors look for: the foundational science, the team, and the data. “Our academic founders Leo James (MRC Laboratory of Molecular Biology) and Will McEwan (UK Dementia Research Institute at the University of Cambridge) discovered and have a really strong understanding of this mechanism, and have so much depth of knowledge between them.”

She elaborates on the strength of the team: “Leo is a structural biologist, so he has a lot of structure function knowledge. I think that in the pre-seed, with the support from initial investors, we managed to pull an experienced team around this. I do think investors look to the team. I was lucky enough to be able to, through my network, with the founders and with Damian Crowther (Entrepreneur-in-Residence at CIC and DDF), put together a complementary skill set of people that understand the neurology space.”

In terms of the team’s expertise, Crowther trained in clinical neurology combined with academic neurodegeneration research, and is the company’s Head of Research.  Head of Medicinal Chemistry, Alex Alanine, led MedChem at Roche in the CNS space, and has brought CNS drugs to market. Thompson says: “I also have an experienced platform chemist who was one of the founders of my previous company, another TPD company, Amphista. He’s got 10 years’ experience out of a preeminent targeted protein degradation lab and he has developed degrader platforms before, so brings that expertise as well. Wrapped around that, we have experienced drug discovery and biotech professionals as well. So, that complementarity of the team, a strong team that’s done this before, is really important.”

Another critical ingredient is TRIMTECH’s differentiation. She says: “We were able to show that the data that had been generated by our founders in expression vectors that express binders to aggregated protein, linked to the active E3 ligase domains of TRIM21. They were able to show impressive data in animal models with those vectorised systems. In the pre-seed and with our founders, we were able to show that you can actually mimic exactly what we see with the natural linker to TRIM21, which is usually an antibody; and replicate this with a small molecule. We had derisked the small molecule approach, and shown  that it’s tractable to this mechanism.”

To conclude, it seems TRIMTECH’s successes to date lie in its unique mechanism, robust foundational science, and experienced team. Moreover, this clear line of sight to clinical application and derisked approach makes a convincing argument for TRIMTECH’s potential to transform treatment for neurodegenerative diseases.